Key TakeawaysKymera Therapeutics shares soared Tuesday, a day after it said partner Sanofi agreed to expand research into its experimental treatment for skin diseases.The biotech firm explained that Sanofi's decision came after an independent review board looked at the safety and efficacy of the drug, known as KT-474.Kymera and Sanofi signed a collaboration agreement in 2020. Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its ...